Arielle Carolina Mora Hurtado, Sarah Gonzalez, Nicole C. Syder, Arthur Manasyan, Tiana Thompson, Lucy Harvey, Jack Rodman, Nada Elbuluk
{"title":"Comorbidities of Primary Scarring Alopecias: A Retrospective Multi-Site Cross-Sectional Study","authors":"Arielle Carolina Mora Hurtado, Sarah Gonzalez, Nicole C. Syder, Arthur Manasyan, Tiana Thompson, Lucy Harvey, Jack Rodman, Nada Elbuluk","doi":"10.1002/jvc2.70015","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>To date, limited research has compared the systemic comorbidities of primary scarring alopecia types. Such research may provide insight into shared disease mechanisms, elucidate novel pathways for therapeutics, and identify those most at risk of comorbidities.</p>\n </section>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To evaluate the prevalences of systemic comorbidities among scarring alopecia types and compare the prevalence of these comorbidities with national United States prevalence.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A retrospective chart review was conducted investigating the systemic comorbidities in patients with scarring alopecia seen at public and private dermatology clinics in Los Angeles between 2018 and 2022.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 240 patients were identified. Compared to other scarring alopecia types, patients with central centrifugal cicatricial alopecia (CCCA) had an increased risk for concomitant traction alopecia (OR 13.98, <i>p</i> < 0.001), concomitant androgenetic alopecia (OR 3.40, <i>p</i> < 0.001), and vitamin D deficiency (OR 1.97, <i>p</i> = 0.039). Compared to the general US population, patients with scarring alopecia, including CCCA and lichen planopilaris/frontal fibrosing alopecia, had a higher prevalence of vitamin D deficiency, metabolic syndrome, depression, anxiety, thyroid disease, uterine fibroids, anemia, atopy, androgenetic alopecia, and breast cancer.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Larger, prospective, population-based studies involving diverse patient groups are needed to differentiate the rates of comorbidities across scarring alopecia types. Dermatologists should consider a thorough review of systems in their patients with scarring alopecia to screen for associated comorbidities, encourage patients to be up to date with age-appropriate screenings, and consider treatment plans that treat associated dermatologic comorbidities along with the primary scarring alopecia.</p>\n </section>\n </div>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"4 2","pages":"482-494"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.70015","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JEADV clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jvc2.70015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background
To date, limited research has compared the systemic comorbidities of primary scarring alopecia types. Such research may provide insight into shared disease mechanisms, elucidate novel pathways for therapeutics, and identify those most at risk of comorbidities.
Objectives
To evaluate the prevalences of systemic comorbidities among scarring alopecia types and compare the prevalence of these comorbidities with national United States prevalence.
Methods
A retrospective chart review was conducted investigating the systemic comorbidities in patients with scarring alopecia seen at public and private dermatology clinics in Los Angeles between 2018 and 2022.
Results
A total of 240 patients were identified. Compared to other scarring alopecia types, patients with central centrifugal cicatricial alopecia (CCCA) had an increased risk for concomitant traction alopecia (OR 13.98, p < 0.001), concomitant androgenetic alopecia (OR 3.40, p < 0.001), and vitamin D deficiency (OR 1.97, p = 0.039). Compared to the general US population, patients with scarring alopecia, including CCCA and lichen planopilaris/frontal fibrosing alopecia, had a higher prevalence of vitamin D deficiency, metabolic syndrome, depression, anxiety, thyroid disease, uterine fibroids, anemia, atopy, androgenetic alopecia, and breast cancer.
Conclusions
Larger, prospective, population-based studies involving diverse patient groups are needed to differentiate the rates of comorbidities across scarring alopecia types. Dermatologists should consider a thorough review of systems in their patients with scarring alopecia to screen for associated comorbidities, encourage patients to be up to date with age-appropriate screenings, and consider treatment plans that treat associated dermatologic comorbidities along with the primary scarring alopecia.
迄今为止,有限的研究比较了原发性瘢痕性脱发类型的全身合并症。这样的研究可能会为共同的疾病机制提供见解,阐明新的治疗途径,并确定那些最危险的合并症。目的评估瘢痕性脱发类型中系统性合并症的患病率,并将这些合并症的患病率与美国全国患病率进行比较。方法回顾性分析2018 - 2022年在洛杉矶公立和私立皮肤科诊所就诊的瘢痕性脱发患者的全身合并症。结果共鉴定出240例患者。与其他瘢痕性脱发类型相比,中心性离心性瘢痕性脱发(CCCA)患者并发牵引性脱发(OR 13.98, p < 0.001)、并发雄性激素源性脱发(OR 3.40, p < 0.001)和维生素D缺乏症(OR 1.97, p = 0.039)的风险增加。与美国普通人群相比,包括CCCA和扁平苔藓/额部纤维化性脱发在内的瘢痕性脱发患者,维生素D缺乏症、代谢综合征、抑郁、焦虑、甲状腺疾病、子宫肌瘤、贫血、特应性、雄激素性脱发和乳腺癌的患病率更高。结论:需要更大规模的、前瞻性的、基于人群的研究,包括不同的患者群体,以区分疤痕性脱发类型的合并症发生率。皮肤科医生应考虑对其瘢痕性脱发患者的系统进行彻底的审查,以筛查相关的合并症,鼓励患者及时进行适合年龄的筛查,并考虑治疗与原发性瘢痕性脱发相关的皮肤合并症的治疗计划。